Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients.

Valot, Benoît; Rognon, Bénédicte; Prenel, Anais; Baraquin, Alice; Knapp, Jenny; Anelli, Mathilde; Richou, Carine; Bresson-Hadni, Solange; Grenouillet, Frederic; Wang, Junhua; Vuitton, Dominique Angèle; Gottstein, Bruno; Millon, Laurence (2017). Screening of antigenic vesicular fluid proteins of Echinococcus multilocularis as potential viability biomarkers to monitor drug response in alveolar echinococcosis patients. Proteomics. Clinical applications, 11(11-12) Wiley 10.1002/prca.201700010

[img] Text
Valot_et_al-2017-PROTEOMICS_-_Clinical_Applications.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (875kB) | Request a copy

PURPOSE The only drugs available to treat alveolar echinococcosis (AE) are mostly parasitostatic and in many cases prescribed for life. Decision criteria for discontinuation rely on the absence of parasitic viability. The aim of the present study is to search for candidate proteins that may exhibit good potential as biomarkers for viability. EXPERIMENTAL DESIGN Sixteen serum samples (five healthy controls, 11 patients with AE), are used. AE-patients are classified into three groups "Cured" (n = 2), "ABZ-responders" (n = 4) and "ABZ-nonresponders" (n = 5). Immunoreactive proteins from vesicular fluid (VF) are identified and quantified by LC-MS/MS analysis after immunoprecipitation (IP) using all 16 serum samples. RESULTS Shotgun analysis of VF lead to the identification of 107 E. multilocularis proteins. Comparative proteomics reveal nine proteins more abundant in IP eluates from ABZ-nonresponder patients (cathepsin b, prosaposin a preprotein, actin modulator protein, fucosidase alpha L1 tissue, gluthatione-S-tranferase, beta galactosidase, elongation factor 2, H17g protein tegumental antigen, and NiemannPick C2 protein). CONCLUSIONS AND CLINICAL RELEVANCE Detection of antibodies against these proteins by ELISA could be helpful to monitor the course of alveolar echinococcosis under albendazole (ABZ) treatment.

Item Type:

Journal Article (Original Article)

Division/Institute:

05 Veterinary Medicine > Research Foci > Host-Pathogen Interaction
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP) > Institute of Parasitology
05 Veterinary Medicine > Department of Infectious Diseases and Pathobiology (DIP)

UniBE Contributor:

Wang, Junhua and Gottstein, Bruno

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health
600 Technology > 630 Agriculture

ISSN:

1862-8346

Publisher:

Wiley

Language:

English

Submitter:

Achim Braun Parham

Date Deposited:

17 May 2018 11:40

Last Modified:

17 May 2018 11:40

Publisher DOI:

10.1002/prca.201700010

PubMed ID:

28697272

Uncontrolled Keywords:

Alveolar echinococcosis immunoproteomics vesicular fluid viability biomarker

BORIS DOI:

10.7892/boris.112386

URI:

https://boris.unibe.ch/id/eprint/112386

Actions (login required)

Edit item Edit item
Provide Feedback